Disease · MONDO_0010911

prolactin-producing pituitary gland adenoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. prolactin-producing pituitary gland adenoma. Diseases, record MONDO_0010911. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0010911

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: prolactin-producing pituitary gland adenoma; Open Targets
Open Targets ID: MONDO_0010911; Open Targets
Other names: PRL producing pituitary gland adenoma, PRL-secreting pituitary adenoma, PRLoma, Pituitary prolactin cell adenoma, familial prolactinoma, lactotrope adenoma, lactotroph adenoma, lactotroph cell adenoma, pituitary adenoma, prolactin-secreting, pituitary gland prolactinoma, pituitary lactotrophic adenoma, pituitary prolactinoma, prolactin producing adenoma of pituitary, prolactin producing adenoma of pituitary gland, prolactin producing adenoma of the pituitary, prolactin producing adenoma of the pituitary gland, prolactin producing pituitary adenoma, prolactin secreting adenoma, prolactin secreting adenoma of pituitary, prolactin secreting adenoma of pituitary gland, prolactin secreting adenoma of the pituitary, prolactin secreting adenoma of the pituitary gland, prolactin secreting pituitary adenoma, prolactin secreting pituitary gland adenoma, prolactinoma, prolactinoma of pituitary, prolactinoma of pituitary gland, prolactinoma of the pituitary, prolactinoma of the pituitary gland; Open Targets
Disease Ontology: DOID:5394; Disease Ontology
MeSH: D015175; MeSH
NCI Thesaurus: C3342; NCI Thesaurus
Orphanet: ORPHA:2965; Orphanet
Highest stage of its drugs: Phase 2/3, for 2 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CABERGOLINE	CHEMBL1201087	Small molecule	Phase 2/3	ClinicalTrials.gov	5	5	5	Drugs and targets
PASIREOTIDE	CHEMBL3349607	Protein	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
LAPATINIB	CHEMBL554	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ROPINIROLE	CHEMBL589	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
CURCUMIN	CHEMBL140	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
BROMOCRIPTINE	CHEMBL493	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
DOPAMINE	CHEMBL59	Small molecule	Unknown	ClinicalTrials.gov	2	2	0	Drugs and targets
CHLOROQUINE	CHEMBL76	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
HYDROXYCHLOROQUINE	CHEMBL1535	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	3	D2-like dopamine receptor agonist; Dopamine D2 receptor agonist	Phase 2/3	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D2-like dopamine receptor	2	D2-like dopamine receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	2	D2-like dopamine receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1815	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	1	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
SSTR1	Somatostatin receptor type 1	1	Somatostatin receptor 1 agonist	Phase 2/3	https://conductscience.org/library/genes/6751	Drugs and targets
SSTR2	Somatostatin receptor type 2	1	Somatostatin receptor 2 agonist	Phase 2/3	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR3	Somatostatin receptor type 3	1	Somatostatin receptor 3 agonist	Phase 2/3	https://conductscience.org/library/genes/6753	Drugs and targets
SSTR5	Somatostatin receptor type 5	1	Somatostatin receptor 5 agonist	Phase 2/3	https://conductscience.org/library/genes/6755	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01620138	Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas	Phase 2/3	21	2016-06-16	Non-functioning Pituitary Adenomas, Prolactinomas	CABERGOLINE, PASIREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT03038308	Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole	Phase 1/2	16	2021-07-30	Hyperprolactinemia, Prolactinoma	ROPINIROLE	Its record names the disease	ClinicalTrials.gov
NCT00939523	Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy	Phase 2	9	2020-01-13	Pituitary Adenomas, Prolactinomas	LAPATINIB	Its record names the disease	ClinicalTrials.gov
NCT06556186	Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma	Not applicable	600		Pituitary Tumor	BROMOCRIPTINE	Its record names the disease	ClinicalTrials.gov
NCT03457389	Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma	Not applicable	68		Pituitary Adenoma, Prolactinoma, Pituitary Tumor, Recurrence Tumor	CABERGOLINE	Its record names the disease	ClinicalTrials.gov
NCT00460616	Cardiac Valve Complications in Prolactinomas Treated With Cabergoline		50		Prolactinomas	CABERGOLINE	Its record names the disease	ClinicalTrials.gov
NCT03717454	Dopamine D2 Receptors(D2R) Imaging in Prolactinomas	Not applicable	50		Prolactinoma	BROMOCRIPTINE, CABERGOLINE	Its record names the disease	ClinicalTrials.gov
NCT01344291	Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients	Phase 1	30		Hyperprolactinoma	CURCUMIN	Its record names the disease	ClinicalTrials.gov
NCT03400865	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	Not applicable	30		Resistance, Disease, Prolactinoma	CABERGOLINE, CHLOROQUINE, HYDROXYCHLOROQUINE	Its record names the disease	ClinicalTrials.gov
NCT06295952	A Study of Pasireotide in People With Prolactinoma	Phase 2	10		Prolactin-Producing Pituitary Tumor	PASIREOTIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Pasireotide vs Cabergoline: serious adverse events	0 of 12	0 of 9	21	NCT01620138

Source Trial comparisons

Papers from its trials19

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28973192	RESULT	1	PubMed
27864853	RESULT	1	PubMed
25024426	RESULT	1	PubMed
21296991	RESULT	1	PubMed
17202454	RESULT	1	PubMed
17202453	RESULT	1	PubMed
16705142	RESULT	1	PubMed
16267335	RESULT	1	PubMed
16148287	RESULT	1	PubMed
15081648	RESULT	1	PubMed

1 to 10 of 19

See all 19 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0010911

GET https://conductscience.org/api/diseases/v1/MONDO_0010911/drugs

API reference For AI assistants